Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Ohio: - Summa Health System - Akron Campus — Akron, Ohio
- Aultman Alliance Community Hospital — Alliance, Ohio
- Summa Health System - Barberton Campus — Barberton, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Ohio: - Summa Health System - Akron Campus — Akron, Ohio
- OhioHealth O'Bleness Hospital — Athens, Ohio
- UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- Summa Health System - Barberton Campus — Barberton, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Aultman Health Foundation — Canton, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Ohio: - Aultman Health Foundation — Canton, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Miami Valley Hospital — Dayton, Ohio
- Premier Blood and Cancer Center — Dayton, Ohio
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Ohio: - Good Samaritan Hospital — Cincinnati, Ohio
- Oncology Hematology Care, Inc. — Cincinnati, Ohio
- Ohio State University CRS — Columbus, Ohio
- Ohio Health Research Institute — Columbus, Ohio
- Columbus NCORP — Columbus, Ohio
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Ohio: - Cleveland Clinic - Mercy Hospital ( Site 0057) — Canton, Ohio
- Tri-County Hematology & Oncology Associates, Inc. ( Site 0076) — Massillon, Ohio
- Taylor Cancer Research Center ( Site 9500) — Maumee, Ohio
- Genesis Healthcare System ( Site 0025) — Zanesville, Ohio
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Ohio: - Gabrail Cancer & Research Center — Canton, Ohio
- Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Ohio: - Research Site — Columbus, Ohio
Phase 3 Recruiting Industry
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, hu…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05646862
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
Phase 2 Recruiting Industry
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…
Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Ohio: - Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Ohio: - The Ohio State University, Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Ohio: - The Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Ohio: - Nationwide Children's Hospital — Colombus, Ohio
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
- Toledo Clinic Cancer Center — Toledo, Ohio
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT06998407
Sites in Ohio: - Avenzo Therapeutics Recruiting Site — Cleveland, Ohio
- Avenzo Therapeutics Recruiting Site — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in Ohio: - Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Ohio: - The Christ Hospital — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…
Sponsor: Gilead Sciences
NCT ID: NCT06657222
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
NCT ID: NCT05985655
Sites in Ohio: - The Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…
Sponsor: GI Innovation, Inc.
NCT ID: NCT05824975
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and tolerable. The cl…
Sponsor: Delcath Systems Inc.
NCT ID: NCT06875128
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- Ohio State University, Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
Phase 2 Recruiting NIH
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for patients at increased risk for breast can…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05941520
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio